The Fig. 4i showed that, Log-rank test suggests that lower expression of CAV2 predicts longer survival (P = 0.0347), while Wilcoxon test does not indicate that expression of CAV2 is co-related with glioma patients’ survival (P = 0.2851). Here, CAV2 is linked to glioma.